Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 12

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

March 31, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$37,076 $36,330 Investments in marketable securities, current75,631 86,293 Accounts receivable1,182 2,409 Prepaid expenses and other current assets2,919 2,284 Total current assets116,808 127,316 Property and equipment, net of accumulated depreciation and impairment of $13,326 (December 31, 2024: $12,996) 168 3,309 Right of use asset— 1,048 Other non-current assets34 34 Total assets$117,010 $131,707 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable and accrued liabilities$12,109 $7,564 Deferred license revenue, current6,759 7,571 Lease liability, current563 483 Total current liabilities19,431 15,618 Liability related to sale of future royalties4,409 4,829 Deferred license revenue, non-current2,863 2,863 Contingent consideration10,524 10,225 Lease liability, non-current626 806 Total liabilities37,853 34,341 Stockholders’ equity  Common sharesAuthorized: unlimited number without par valueIssued and outstanding: 191,481,474(December 31, 2024: 189,963,492)1,416,332 1,410,025 Additional paid-in capital82,089 82,048 Deficit(1,371,098)(1,346,572)Accumulated other comprehensive loss(48,166)(48,135)Total stockholders’ equity79,157 97,366 Total liabilities and stockholders’ equity$117,010 $131,707 

See accompanying notes to the condensed consolidated financial statements.

1

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands of U.S. Dollars, except share and per share amounts)

Three Months Ended March 31,20252024RevenueCollaborations and